Interní Med. 2010; 12(10): 479-481

Antiplatelet and anti-inflammatory effect of statins

MUDr.Zoltán Paluch, Ph.D., Mgr.Zlata Heřmánková
I. interní klinika FTN-IPVZ, Praha

The paper provides a short general introduction to and an overview of antiplatelet and anti-inflammatory effect of statins. The underlying

pathophysiology, mechanism and significance for clinical practice are briefly mentioned. The areas that are still subject to intensive

research are outlined.

Keywords: 3-hydroxy-3 methylglutaryl-coenzym A, statins, antiaggregation effect, antiinflammatory effects

Published: November 15, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Paluch Z, Heřmánková Z. Antiplatelet and anti-inflammatory effect of statins. Interní Med. 2010;12(10):479-481.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mori-Kawabe M, Tsushima H, Fujimoto S, et al. Role of Rho/Rho-kinase and NO/cGMP signaling pathways in vascular function prior to atherosclerosis. J Atheroscler Thromb. 2009; 16(6): 722-732. Go to original source... Go to PubMed...
    2. Qian Z, James KL. Pleiotropic effects of statins - basic research and clinical perspectives. Circulation Journal 2010; 74: 818-826. Go to original source... Go to PubMed...
    3. Ravingerová T, Adameová A, Kelly T, et al. Changes in PPAR gene expression and myocardial tolerance to ischaemia: relevance to pleiotropic effects of statins. Can. J Physiol Pharmacol. 2009; 87(12): 1028-1036. Go to original source... Go to PubMed...
    4. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood Coagulation. Arterioscler Thromb Vasc Biol. 2005; 25: 287. Go to original source... Go to PubMed...
    5. Balk EM, Lau J, Doudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease. Ann Intern Med. 2003; 139: 670-682. Go to original source... Go to PubMed...
    6. Karatzis K, Lekakis J, Papamichael C, et al. Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina. Int J Cardiol. 2005; 101: 65-70. Go to original source... Go to PubMed...
    7. Omori H, Nagashima H, Tsurumi Y, et al. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol. 2002; 54: 395-399. Go to original source... Go to PubMed...
    8. Pretnar-Oblak J, Sabovic M, Sebestjen M, et al. Influence of atorvastatin treatment on L-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions. Stroke 2006; 37: 2540-2545. Go to original source... Go to PubMed...
    9. Yemisci M, Ay H, Koacefe C, et al. Statin potentiates human platelet eNOS activity without enhancing eNOS mRNA and protein levels. Cerebrovasc Di. 2008; 26: 190-198. Go to original source... Go to PubMed...
    10. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endotheal dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-1457. Go to original source... Go to PubMed...
    11. Shaw SM, Fildes EJ, Yonan N, Williams SG. Pleiotropic effects and cholesterol-lowering therapy. Cardiology 2009; 112: 4-12. Go to original source... Go to PubMed...
    12. Cannon CP. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll. 2006; 48: 438-445. Go to original source... Go to PubMed...
    13. Scirica BM. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE ITTIMI 22 study. J Am Coll Cardiol. 2006; 47: 2326-2331. Go to original source... Go to PubMed...
    14. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol. 2002; 22: 1524-1534. Go to original source... Go to PubMed...
    15. Takemoto M, Liao JK. Pleiotropic Effects of 3-Hydroxy-3Methylglutaryl Coenzyme A Reductase Inhibitors Arteriosclerosis. Thrombosis and Vascular Biology 2001; 21: 1712-1719. Go to original source... Go to PubMed...
    16. Perler AB. The effect of statin medications on perioperative and long-term outcomes following carotid endarterectomy or stenting. Semin Vasc Surg. 2007; 20: 252-258. Go to original source... Go to PubMed...
    17. Walter DH. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow derived endothelial progenitor cells. Circulation 2002; 105: 3017-3024. Go to original source... Go to PubMed...
    18. Arslan F, Pasterkamp G, de Kleijn DP. Unraveling pleiotropic effects of statins. Circ res. 2008; 103: 334-336. Go to original source... Go to PubMed...
    19. Rav KK, Cannon CHP. Lipid-independent pleiotropic effects of statins in the management of acute coronary syndromes. Curr Treatm opt in card med. 2007; 9: 46-51. Go to original source... Go to PubMed...
    20. Eto M. Statin prevents tissu factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002. Go to original source...
    21. Balk EM, Lau J, Doudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease. Ann Intern Med. 2003; 139: 670-682. Go to original source... Go to PubMed...
    22. Eikelboom JW, Hankey GJ, Thom J, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid determinants and effect on cardiovascular risk. Circulation 2008; 118: 1705-1712. Go to original source... Go to PubMed...
    23. Naghavi M. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664-1672. Go to original source... Go to PubMed...
    24. Naghavi M. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003; 108: 1772-1778. Go to original source... Go to PubMed...
    25. Kirmizis D, Chatzidimitriou D. Pleiotropic vasoprotective effects of statins: The chicken or the egg? Drug Des Dev and Ther. 2009; 3: 191-204. Go to original source... Go to PubMed...
    26. Tousolis D, Antoniades Ch, Stefanidis CH. Statins ameliorate atherosclerosis induced by inhibition of nitric oxide synthase: another novel vascular protective mechanism? Int J Cardiol. 2008; 123: 91-93. Go to original source... Go to PubMed...
    27. Lodi S, Evans SJ, Egger P, Carpenter J. Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. Br J Clin Pharmacol. 2010; 69: 85-94. Go to original source... Go to PubMed...
    28. Ky B, Rader DJ. The effects of statin therapy on plasma markers of inflammation in patients without cardiovascular disease. Clin Cardiol. 2005; 28: 67-70. Go to original source... Go to PubMed...
    29. Shankar A, Li J, Nieto FJ, et al. Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension. Am Heart J. 2007; 154: 495-501. Go to original source... Go to PubMed...
    30. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovasciuar events. N Eng J Med. 2002; 347: 1557-1565. Go to original source... Go to PubMed...
    31. Fichtlscherer S. Eievated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000-1006. Go to original source... Go to PubMed...
    32. Nežič L, Škrbič R, Dobrič S, et al. Simvastatin and indomethacin have similar anti-inflammatory activity in a rat model of acute local inflammation. Bas Clin Pharm Tox. 2009; 104(3): 185-191. Go to original source... Go to PubMed...
    33. Di Pasquale P, Cannizzaro S, Fasullo S, et al. Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminaiy findings. Clin Sci. 2007; 113(11): 443-448. Go to original source... Go to PubMed...
    34. Foussef S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84. Go to original source... Go to PubMed...
    35. Vollmer T. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607-1608. Go to original source... Go to PubMed...
    36. Wolozin B. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-1443. Go to original source... Go to PubMed...
    37. Mori-Kawabe M, Tsushima H, Fujimoto S, et al. Role of Rho/Rho-kinase and NO/cGMP signaling pathways in vascular function prior to atherosclerosis. J Atheroscler Thromb. 2009; 16(6): 722-732. Go to original source... Go to PubMed...
    38. Qian Z, James KL. Pleiotropic effects of statins - basic research and clinical perspectives. Circulation Journal 2010; 74: 818-826. Go to original source... Go to PubMed...
    39. Ravingerová T, Adameová A, Kelly T, et al. Changes in PPAR gene expression and myocardial tolerance to ischaemia: relevance to pleiotropic effects of statins. Can. J Physiol Pharmacol. 2009; 87(12): 1028-1036. Go to original source... Go to PubMed...
    40. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood Coagulation. Arterioscler Thromb Vasc Biol. 2005; 25: 287. Go to original source... Go to PubMed...
    41. Balk EM, Lau J, Doudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease. Ann Intern Med. 2003; 139: 670-682. Go to original source... Go to PubMed...
    42. Karatzis K, Lekakis J, Papamichael C, et al. Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina. Int J Cardiol. 2005; 101: 65-70. Go to original source... Go to PubMed...
    43. Omori H, Nagashima H, Tsurumi Y, et al. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol. 2002; 54: 395-399. Go to original source... Go to PubMed...
    44. Pretnar-Oblak J, Sabovic M, Sebestjen M, et al. Influence of atorvastatin treatment on L-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions. Stroke 2006; 37: 2540-2545. Go to original source... Go to PubMed...
    45. Yemisci M, Ay H, Koacefe C, et al. Statin potentiates human platelet eNOS activity without enhancing eNOS mRNA and protein levels. Cerebrovasc Di. 2008; 26: 190-198. Go to original source... Go to PubMed...
    46. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endotheal dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-1457. Go to original source... Go to PubMed...
    47. Shaw SM, Fildes EJ, Yonan N, Williams SG. Pleiotropic effects and cholesterol-lowering therapy. Cardiology 2009; 112: 4-12. Go to original source... Go to PubMed...
    48. Cannon CP. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll. 2006; 48: 438-445. Go to original source... Go to PubMed...
    49. Scirica BM. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE ITTIMI 22 study. J Am Coll Cardiol. 2006; 47: 2326-2331. Go to original source... Go to PubMed...
    50. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol. 2002; 22: 1524-1534. Go to original source... Go to PubMed...
    51. Takemoto M, Liao JK. Pleiotropic Effects of 3-Hydroxy-3Methylglutaryl Coenzyme A Reductase Inhibitors Arteriosclerosis. Thrombosis and Vascular Biology 2001; 21: 1712-1719. Go to original source... Go to PubMed...
    52. Perler AB. The effect of statin medications on perioperative and long-term outcomes following carotid endarterectomy or stenting. Semin Vasc Surg. 2007; 20: 252-258. Go to original source... Go to PubMed...
    53. Walter DH. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow derived endothelial progenitor cells. Circulation 2002; 105: 3017-3024. Go to original source... Go to PubMed...
    54. Arslan F, Pasterkamp G, de Kleijn DP. Unraveling pleiotropic effects of statins. Circ res. 2008; 103: 334-336. Go to original source... Go to PubMed...
    55. Rav KK, Cannon CHP. Lipid-independent pleiotropic effects of statins in the management of acute coronary syndromes. Curr Treatm opt in card med. 2007; 9: 46-51. Go to original source... Go to PubMed...
    56. Eto M. Statin prevents tissu factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002. Go to original source...
    57. Balk EM, Lau J, Doudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease. Ann Intern Med. 2003; 139: 670-682. Go to original source... Go to PubMed...
    58. Eikelboom JW, Hankey GJ, Thom J, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid determinants and effect on cardiovascular risk. Circulation 2008; 118: 1705-1712. Go to original source... Go to PubMed...
    59. Naghavi M. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664-1672. Go to original source... Go to PubMed...
    60. Naghavi M. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003; 108: 1772-1778. Go to original source... Go to PubMed...
    61. Kirmizis D, Chatzidimitriou D. Pleiotropic vasoprotective effects of statins: The chicken or the egg? Drug Des Dev and Ther. 2009; 3: 191-204. Go to original source... Go to PubMed...
    62. Tousolis D, Antoniades Ch, Stefanidis CH. Statins ameliorate atherosclerosis induced by inhibition of nitric oxide synthase: another novel vascular protective mechanism? Int J Cardiol. 2008; 123: 91-93. Go to original source... Go to PubMed...
    63. Lodi S, Evans SJ, Egger P, Carpenter J. Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. Br J Clin Pharmacol. 2010; 69: 85-94. Go to original source... Go to PubMed...
    64. Ky B, Rader DJ. The effects of statin therapy on plasma markers of inflammation in patients without cardiovascular disease. Clin Cardiol. 2005; 28: 67-70. Go to original source... Go to PubMed...
    65. Shankar A, Li J, Nieto FJ, et al. Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension. Am Heart J. 2007; 154: 495-501. Go to original source... Go to PubMed...
    66. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovasciuar events. N Eng J Med. 2002; 347: 1557-1565. Go to original source... Go to PubMed...
    67. Fichtlscherer S. Eievated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000-1006. Go to original source... Go to PubMed...
    68. Nežič L, Škrbič R, Dobrič S, et al. Simvastatin and indomethacin have similar anti-inflammatory activity in a rat model of acute local inflammation. Bas Clin Pharm Tox. 2009; 104(3): 185-191. Go to original source... Go to PubMed...
    69. Di Pasquale P, Cannizzaro S, Fasullo S, et al. Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminaiy findings. Clin Sci. 2007; 113(11): 443-448. Go to original source... Go to PubMed...
    70. Foussef S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84. Go to original source... Go to PubMed...
    71. Vollmer T. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607-1608. Go to original source... Go to PubMed...
    72. Wolozin B. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-1443. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.